Search Results

You are looking at 91 - 100 of 258 items for :

  • "oxaliplatin" x
  • Refine by Access: All x
Clear All
Full access

Joleen M. Hubbard and Axel Grothey

should undergo 6 months of oxaliplatin-based therapy with either modified FOLFOX6 (5-FU, leucovorin, oxaliplatin) or XELOX (capecitabine, oxaliplatin), which have been shown to improve outcomes in randomized phase III clinical trials. 36 , 37 Patients

Full access

Al B. Benson III, Alan P. Venook, Mahmoud M. Al-Hawary, Nilofer Azad, Yi-Jen Chen, Kristen K. Ciombor, Stacey Cohen, Harry S. Cooper, Dustin Deming, Ignacio Garrido-Laguna, Jean L. Grem, Andrew Gunn, J. Randolph Hecht, Sarah Hoffe, Joleen Hubbard, Steven Hunt, William Jeck, Kimberly L. Johung, Natalie Kirilcuk, Smitha Krishnamurthi, Jennifer K. Maratt, Wells A. Messersmith, Jeffrey Meyerhardt, Eric D. Miller, Mary F. Mulcahy, Steven Nurkin, Michael J. Overman, Aparna Parikh, Hitendra Patel, Katrina Pedersen, Leonard Saltz, Charles Schneider, David Shibata, John M. Skibber, Constantinos T. Sofocleous, Eden Stotsky-Himelfarb, Anna Tavakkoli, Christopher G. Willett, Kristina Gregory, and Lisa Gurski

mitigate that risk. Results of a multi-institutional, single-arm, open-label, nonrandomized, phase II trial suggest that chemoradiotherapy with CAPEOX (capecitabine, oxaliplatin) followed by local excision may be a safe alternative to transabdominal

Full access

Al B. Benson III, Alan P. Venook, Mahmoud M. Al-Hawary, Lynette Cederquist, Yi-Jen Chen, Kristen K. Ciombor, Stacey Cohen, Harry S. Cooper, Dustin Deming, Paul F. Engstrom, Jean L. Grem, Axel Grothey, Howard S. Hochster, Sarah Hoffe, Steven Hunt, Ahmed Kamel, Natalie Kirilcuk, Smitha Krishnamurthi, Wells A. Messersmith, Jeffrey Meyerhardt, Mary F. Mulcahy, James D. Murphy, Steven Nurkin, Leonard Saltz, Sunil Sharma, David Shibata, John M. Skibber, Constantinos T. Sofocleous, Elena M. Stoffel, Eden Stotsky-Himelfarb, Christopher G. Willett, Evan Wuthrick, Kristina M. Gregory, Lisa Gurski, and Deborah A. Freedman-Cass

chemoRT therapy. 130 , 131 The randomized NSABP R-04 trial examined the preoperative use of infusional 5-FU ± oxaliplatin versus capecitabine ± oxaliplatin in 1,608 patients with stage II or III rectal cancer. 131 , 132 No differences in locoregional

Full access

Kimberly L. Johung and Stacey M. Stein

evolved after the FLOT4-AIO trial was presented at the 2017 ASCO Annual Meeting. Perioperative ECF was compared with perioperative FLOT (docetaxel/oxaliplatin/fluorouracil/leucovorin), with median overall survival (OS) improving from 35 to 50 months with

Full access

Robert J. Motzer, Neeraj Agarwal, Clair Beard, Graeme B. Bolger, Barry Boston, Michael A. Carducci, Toni K. Choueiri, Robert A. Figlin, Mayer Fishman, Steven L. Hancock, Gary R. Hudes, Eric Jonasch, Anne Kessinger, Timothy M. Kuzel, Paul H. Lange, Ellis G. Levine, Kim A. Margolin, M. Dror Michaelson, Thomas Olencki, Roberto Pili, Bruce G. Redman, Cary N. Robertson, Lawrence H. Schwartz, Joel Sheinfeld, and Jue Wang

with non-seminomatous germ-cell tumors and elevated serum tumor markers . Cancer 1992 ; 70 : 2354 – 2357 . 36 Pectasides D Pectasides M Farmakis D . Gemcitabine and oxaliplatin (GEMOX) in patients with cisplatin-refractory germ cell

Full access

Christopher G. Willett

is an example. The former guidelines listed FOLFOX (5-fluorouracil/leucovorin/oxaliplatin) as a preferred option for stage II rectal cancer, but for stage II colon cancer the recommendation was fluoropyrimidine without oxaliplatin as postoperative

Full access

Axel Grothey

,” oxaliplatin, and continue the remaining drugs, with bevacizumab, until progression. “This is how to optimize the use of first-line bevacizumab,” he indicated. Clinical synergy is observed when bevacizumab is given with a fluoropyrimidine, a first

Full access

Parvin F. Peddi and Andrea Wang-Gillam

. Because of extensive venous vascular involvement, the patient was started on gemcitabine and oxaliplatin combination therapy. After 4 cycles, CA 19-9 decreased dramatically from 260 to 27 ng/mL. Repeat CT showed tumor shrinkage of the mass to 2.7 × 2.1 cm

Full access

Jaffer A. Ajani, Thomas A. D'Amico, Khaldoun Almhanna, David J. Bentrem, Joseph Chao, Prajnan Das, Crystal S. Denlinger, Paul Fanta, Farhood Farjah, Charles S. Fuchs, Hans Gerdes, Michael Gibson, Robert E. Glasgow, James A. Hayman, Steven Hochwald, Wayne L. Hofstetter, David H. Ilson, Dawn Jaroszewski, Kimberly L. Johung, Rajesh N. Keswani, Lawrence R. Kleinberg, W. Michael Korn, Stephen Leong, Catherine Linn, A. Craig Lockhart, Quan P. Ly, Mary F. Mulcahy, Mark B. Orringer, Kyle A. Perry, George A. Poultsides, Walter J. Scott, Vivian E. Strong, Mary Kay Washington, Benny Weksler, Christopher G. Willett, Cameron D. Wright, Debra Zelman, Nicole McMillian, and Hema Sundar

, and fluorouracil). 51 , 53 The combination of fluorouracil, leucovorin, and oxaliplatin (FLO) was evaluated as an alternative to fluorouracil and cisplatin for advanced or metastatic gastric cancer. 54 – 56 A phase III trial conducted by the German

Full access

capecitabine in patients with metastatic colorectal cancer refractory to irinotecan- and oxaliplatin-based therapy. The study will include an abbreviated phase I dose-finding portion, followed by a nonrandomized phase II component. Nintedanib and capecitabine